ACS Medicinal Chemistry Letters最新文献_第8页

Peptide Aldehydes Incorporating Thiazol-4-yl Alanine Are Potent In Vitro Inhibitors of SARS-CoV-2 Main Protease. 含有噻唑-4-基丙氨酸的肽醛是 SARS-CoV-2 主要蛋白酶的强效体外抑制剂

IF 3.5 3区医学

ACS Medicinal Chemistry Letters Pub Date : 2024-11-03 eCollection Date: 2024-11-14 DOI: 10.1021/acsmedchemlett.4c00444

Jenson R Feys, Kyle Edwards, Michael A Joyce, Holly A Saffran, Justin A Shields, Kassandra Garcia, D Lorne Tyrrell, Conrad Fischer

{"title":"Peptide Aldehydes Incorporating Thiazol-4-yl Alanine Are Potent In Vitro Inhibitors of SARS-CoV-2 Main Protease.","authors":"Jenson R Feys, Kyle Edwards, Michael A Joyce, Holly A Saffran, Justin A Shields, Kassandra Garcia, D Lorne Tyrrell, Conrad Fischer","doi":"10.1021/acsmedchemlett.4c00444","DOIUrl":"10.1021/acsmedchemlett.4c00444","url":null,"abstract":"The main protease of SARS-CoV-2 is an essential enzyme required for polyprotein cleavage during viral replication and thus is an excellent target for development of direct-acting antiviral compounds. Continued research efforts have elucidated several peptidic small molecules like GC376, boceprevir, and nirmatrelvir with potent anticoronaviral activity bearing optimized amino acid side chain residues. To reduce synthetic complexity and cost, we used simple chemical surrogates that were commercially readily available to develop new inhibitors that mimic the potency of these drug compounds. We synthesized and tested several analogue chimeras of GC376 and boceprevir that have surrogate residues at the P1 and/or P2 position in order to further improve target binding. Both P1 variants with either a nonpolar cyclobutyl or polar thiazol-4-yl alanine resulted in low-micromolar to submicromolar Mpro inhibitors with strong antiviral activity in cell assays.","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"15 11","pages":"2046-2052"},"PeriodicalIF":3.5,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142674567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Machine Learning to Predict Potential Energy Surface of Resveratrol Drug: A Quantum-Level Calculation. 机器学习预测白藜芦醇药物的势能面：量子级计算。

IF 3.5 3区医学

ACS Medicinal Chemistry Letters Pub Date : 2024-11-01 eCollection Date: 2024-11-14 DOI: 10.1021/acsmedchemlett.4c00382

Hossein Shirani, Seyed Majid Hashemianzadeh

引用次数: 0

Machine Learning to Predict Potential Energy Surface of Resveratrol Drug: A Quantum-Level Calculation 机器学习预测白藜芦醇药物的势能面：量子级计算

IF 3.5 3区医学

ACS Medicinal Chemistry Letters Pub Date : 2024-11-01 DOI: 10.1021/acsmedchemlett.4c0038210.1021/acsmedchemlett.4c00382

Hossein Shirani*, and , Seyed Majid Hashemianzadeh*,

引用次数: 0

Design, Synthesis, and Biological Evaluation of a Series of Spiro Analogues as Novel HPK1 Inhibitors 作为新型 HPK1 抑制剂的一系列螺环类似物的设计、合成和生物学评价

IF 3.5 3区医学

ACS Medicinal Chemistry Letters Pub Date : 2024-10-30 DOI: 10.1021/acsmedchemlett.4c0043410.1021/acsmedchemlett.4c00434

Jingjing Peng, Xiaoyu Ding, Celia X. J. Chen, Pei-Yu Shih, Qingyuan Meng, Xiao Ding, Man Zhang, Alex Aliper, Feng Ren, Hongfu Lu* and Alex Zhavoronkov*,

{"title":"Design, Synthesis, and Biological Evaluation of a Series of Spiro Analogues as Novel HPK1 Inhibitors","authors":"Jingjing Peng, Xiaoyu Ding, Celia X. J. Chen, Pei-Yu Shih, Qingyuan Meng, Xiao Ding, Man Zhang, Alex Aliper, Feng Ren, Hongfu Lu* and Alex Zhavoronkov*, ","doi":"10.1021/acsmedchemlett.4c0043410.1021/acsmedchemlett.4c00434","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.4c00434https://doi.org/10.1021/acsmedchemlett.4c00434","url":null,"abstract":"Hematopoietic progenitor kinase 1 (HPK1) negatively affects T cell activation and proliferation and is a promising target for immunotherapy. Although HPK1 inhibitors have shown promising efficacy in preclinical models, none have been approved for clinical use. One significant challenge in developing an HPK1 inhibitor is the difficulty in designing a potent inhibitor with good kinase selectivity and pharmacokinetic properties. Here, we report a series of spiro HPK1 inhibitors with good potency and selectivity. Specifically, compound 16 exhibited potent HPK1 inhibition (IC50 = 2.67 nM), adequate selectivity toward the MAP4K family (>100-fold), and good selectivity against selected kinases (>300-fold). Compound 16 demonstrated moderate in vivo clearance and reasonable oral exposure in mice and rats. Notably, compound 16 possessed good antitumor efficacy in the CT26 murine colon cancer and a synergistic effect when combined with anti-PD-1. These exciting preclinical results support the continued development of this class of HPK1 inhibitors.","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"15 11","pages":"2032–2041 2032–2041"},"PeriodicalIF":3.5,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel Phenylpiperidine Derivatives as QPCT and QPCTL Inhibitors for Treating Cancer or Fibrotic Diseases 作为治疗癌症或纤维化疾病的 QPCT 和 QPCTL 抑制剂的新型苯基哌啶衍生物

IF 3.5 3区医学

ACS Medicinal Chemistry Letters Pub Date : 2024-10-30 DOI: 10.1021/acsmedchemlett.4c0049510.1021/acsmedchemlett.4c00495

Ram W. Sabnis*,

引用次数: 0

Novel Phenylpiperidine Derivatives as QPCT and QPCTL Inhibitors for Treating Cancer or Fibrotic Diseases. 作为治疗癌症或纤维化疾病的 QPCT 和 QPCTL 抑制剂的新型苯基哌啶衍生物。

IF 3.5 3区医学

ACS Medicinal Chemistry Letters Pub Date : 2024-10-30 eCollection Date: 2024-11-14 DOI: 10.1021/acsmedchemlett.4c00495

Ram W Sabnis

引用次数: 0

Discovery of PARP1-Sparing Inhibitors for Protein ADP-Ribosylation 发现 PARP1 蛋白质 ADP-核糖基化分离抑制剂

IF 3.5 3区医学

ACS Medicinal Chemistry Letters Pub Date : 2024-10-30 DOI: 10.1021/acsmedchemlett.4c0039510.1021/acsmedchemlett.4c00395

Elisa N. Stephens, Liang-Chieh Chen, Arshad J. Ansari, Kaiyu Shen, Lei Zhang, Steven G. Guillen, Clay C. C. Wang and Yong Zhang*,

引用次数: 0

Discovery of PARP1-Sparing Inhibitors for Protein ADP-Ribosylation. 发现 PARP1 蛋白质 ADP-核糖基化分离抑制剂

IF 3.5 3区医学

ACS Medicinal Chemistry Letters Pub Date : 2024-10-30 eCollection Date: 2024-11-14 DOI: 10.1021/acsmedchemlett.4c00395

Elisa N Stephens, Liang-Chieh Chen, Arshad J Ansari, Kaiyu Shen, Lei Zhang, Steven G Guillen, Clay C C Wang, Yong Zhang

引用次数: 0

Design, Synthesis, and Biological Evaluation of a Series of Spiro Analogues as Novel HPK1 Inhibitors. 作为新型 HPK1 抑制剂的一系列螺环类似物的设计、合成和生物学评价。

IF 3.5 3区医学

ACS Medicinal Chemistry Letters Pub Date : 2024-10-30 eCollection Date: 2024-11-14 DOI: 10.1021/acsmedchemlett.4c00434

Jingjing Peng, Xiaoyu Ding, Celia X J Chen, Pei-Yu Shih, Qingyuan Meng, Xiao Ding, Man Zhang, Alex Aliper, Feng Ren, Hongfu Lu, Alex Zhavoronkov

{"title":"Design, Synthesis, and Biological Evaluation of a Series of Spiro Analogues as Novel HPK1 Inhibitors.","authors":"Jingjing Peng, Xiaoyu Ding, Celia X J Chen, Pei-Yu Shih, Qingyuan Meng, Xiao Ding, Man Zhang, Alex Aliper, Feng Ren, Hongfu Lu, Alex Zhavoronkov","doi":"10.1021/acsmedchemlett.4c00434","DOIUrl":"10.1021/acsmedchemlett.4c00434","url":null,"abstract":"Hematopoietic progenitor kinase 1 (HPK1) negatively affects T cell activation and proliferation and is a promising target for immunotherapy. Although HPK1 inhibitors have shown promising efficacy in preclinical models, none have been approved for clinical use. One significant challenge in developing an HPK1 inhibitor is the difficulty in designing a potent inhibitor with good kinase selectivity and pharmacokinetic properties. Here, we report a series of spiro HPK1 inhibitors with good potency and selectivity. Specifically, compound 16 exhibited potent HPK1 inhibition (IC50 = 2.67 nM), adequate selectivity toward the MAP4K family (>100-fold), and good selectivity against selected kinases (>300-fold). Compound 16 demonstrated moderate in vivo clearance and reasonable oral exposure in mice and rats. Notably, compound 16 possessed good antitumor efficacy in the CT26 murine colon cancer and a synergistic effect when combined with anti-PD-1. These exciting preclinical results support the continued development of this class of HPK1 inhibitors.","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"15 11","pages":"2032-2041"},"PeriodicalIF":3.5,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142674517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bicyclic Ureas as JAK2 Inhibitors for Treating Hematological Cancer. 双环脲类作为 JAK2 抑制剂治疗血液肿瘤

IF 3.5 3区医学

ACS Medicinal Chemistry Letters Pub Date : 2024-10-29 eCollection Date: 2024-11-14 DOI: 10.1021/acsmedchemlett.4c00496

Ram W Sabnis

引用次数: 0